Partnership ExoVectory & Erasmus MC: Health Holland funding to develop exosome cancer therapy

Erasmus MC, ExoVectory and biotech company Applikon-Getinge have obtained subsidy from the Dutch TKI (Topconsortia voor Kennis en Innovatie), Health Holland fund to develop ExoVectory’s exosome technology for treatment of highly aggressive metastasized prostate cancer. With this (3yr) project ExoVectory further strengthens its research collaborations with Erasmus MC, to prepare its exosome technology as a tool for treatment of highly aggressive cancers, such as (metastasized) prostate cancer and brain cancer.

Explore our exosome delivery technology or contact ExoVectory about partnerships and investment.